Matches in SemOpenAlex for { <https://semopenalex.org/work/W1854667071> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W1854667071 endingPage "1568" @default.
- W1854667071 startingPage "1563" @default.
- W1854667071 abstract "We reviewed the medical records of 110 consecutive patients at our institution who had acute leukemia and received high-dose cytarabine (Ara-C; HDAC) in order to analyze risk factors associated with HDAC neurotoxicity (NT). There were adequate records on 101 patients who received 147 courses of HDAC. Twenty-six treatment courses (18%) were complicated by NT. The median time of NT onset was 5 days (range, 1 to 10 days), and NT was reversible in 16 of 21 survivors (76%). Patients with severe NT (grades 3 to 4) were less likely to have complete reversal of their neurological deficit than those with mild NT (P less than .1). In our patients, there was no significant association between previously described risk factors (age over 49 years, male gender, CNS disorder, and cumulative HDAC dose greater than 48 g/m2) and incidence of NT. However, treatment courses involving HDAC given during renal insufficiency (serum creatinine greater than or equal to 1.5 mg/dL or an increase in serum creatinine greater than 0.5 mg/dL) were much more likely to be complicated by any degree of NT during administration of HDAC (62%) and severe NT (42%) than those given during normal renal function (8% and 3%, respectively; P less than .001). Of the treatment courses involving patients with estimated creatinine clearances less than 60 mL/min, 76% were complicated by NT compared with 8% of treatment courses involving patients with clearances greater than 60 mL/min (P less than .001). HDAC courses with neurotoxic patients had higher serum creatinines (2.1 +/- 1.4 v 1.1 +/- 0.6 mg/dL), greater increases in serum creatinine (+ 0.5 +/- 0.8 v + 0.07 +/- 0.3 mg/dL), and lower estimated creatinine clearances (61 +/- 35 v 91 +/- 29 mL/min) than those courses with nonneurotoxic patients (P less than .001, all parameters). Patients receiving HDAC during renal insufficiency are at high risk for developing NT. Dose reduction of HDAC should be considered for patients with renal insufficiency." @default.
- W1854667071 created "2016-06-24" @default.
- W1854667071 creator A5012400900 @default.
- W1854667071 creator A5028408074 @default.
- W1854667071 creator A5068495779 @default.
- W1854667071 date "1989-10-01" @default.
- W1854667071 modified "2023-09-25" @default.
- W1854667071 title "The association between high-dose cytarabine neurotoxicity and renal insufficiency." @default.
- W1854667071 doi "https://doi.org/10.1200/jco.1989.7.10.1563" @default.
- W1854667071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2778484" @default.
- W1854667071 hasPublicationYear "1989" @default.
- W1854667071 type Work @default.
- W1854667071 sameAs 1854667071 @default.
- W1854667071 citedByCount "54" @default.
- W1854667071 countsByYear W18546670712012 @default.
- W1854667071 countsByYear W18546670712016 @default.
- W1854667071 countsByYear W18546670712017 @default.
- W1854667071 countsByYear W18546670712018 @default.
- W1854667071 countsByYear W18546670712020 @default.
- W1854667071 countsByYear W18546670712021 @default.
- W1854667071 countsByYear W18546670712022 @default.
- W1854667071 crossrefType "journal-article" @default.
- W1854667071 hasAuthorship W1854667071A5012400900 @default.
- W1854667071 hasAuthorship W1854667071A5028408074 @default.
- W1854667071 hasAuthorship W1854667071A5068495779 @default.
- W1854667071 hasConcept C120665830 @default.
- W1854667071 hasConcept C121332964 @default.
- W1854667071 hasConcept C126322002 @default.
- W1854667071 hasConcept C126894567 @default.
- W1854667071 hasConcept C141071460 @default.
- W1854667071 hasConcept C159641895 @default.
- W1854667071 hasConcept C2776694085 @default.
- W1854667071 hasConcept C2778041864 @default.
- W1854667071 hasConcept C2779491297 @default.
- W1854667071 hasConcept C2780306776 @default.
- W1854667071 hasConcept C29730261 @default.
- W1854667071 hasConcept C61511704 @default.
- W1854667071 hasConcept C71924100 @default.
- W1854667071 hasConcept C90924648 @default.
- W1854667071 hasConceptScore W1854667071C120665830 @default.
- W1854667071 hasConceptScore W1854667071C121332964 @default.
- W1854667071 hasConceptScore W1854667071C126322002 @default.
- W1854667071 hasConceptScore W1854667071C126894567 @default.
- W1854667071 hasConceptScore W1854667071C141071460 @default.
- W1854667071 hasConceptScore W1854667071C159641895 @default.
- W1854667071 hasConceptScore W1854667071C2776694085 @default.
- W1854667071 hasConceptScore W1854667071C2778041864 @default.
- W1854667071 hasConceptScore W1854667071C2779491297 @default.
- W1854667071 hasConceptScore W1854667071C2780306776 @default.
- W1854667071 hasConceptScore W1854667071C29730261 @default.
- W1854667071 hasConceptScore W1854667071C61511704 @default.
- W1854667071 hasConceptScore W1854667071C71924100 @default.
- W1854667071 hasConceptScore W1854667071C90924648 @default.
- W1854667071 hasIssue "10" @default.
- W1854667071 hasLocation W18546670711 @default.
- W1854667071 hasLocation W18546670712 @default.
- W1854667071 hasOpenAccess W1854667071 @default.
- W1854667071 hasPrimaryLocation W18546670711 @default.
- W1854667071 hasRelatedWork W1544023406 @default.
- W1854667071 hasRelatedWork W1830795151 @default.
- W1854667071 hasRelatedWork W1973741567 @default.
- W1854667071 hasRelatedWork W1974378936 @default.
- W1854667071 hasRelatedWork W2014603468 @default.
- W1854667071 hasRelatedWork W2046899919 @default.
- W1854667071 hasRelatedWork W2093874596 @default.
- W1854667071 hasRelatedWork W3117263584 @default.
- W1854667071 hasRelatedWork W393698729 @default.
- W1854667071 hasRelatedWork W4296385806 @default.
- W1854667071 hasVolume "7" @default.
- W1854667071 isParatext "false" @default.
- W1854667071 isRetracted "false" @default.
- W1854667071 magId "1854667071" @default.
- W1854667071 workType "article" @default.